Pharmaceutical News

RSS

WHO report: Access to new medicines requires transparency, collaboration

As the number of new medicines introduced in Europe rises, governments are finding it increasingly difficult to afford them, according to a comprehensive study released today by the WHO Regional Office for Europe.

27 Mar 2015

Helsinn, Mundipharma sign distribution and license agreement for anamorelin

Helsinn, a Swiss Group focused on building quality cancer care, and Mundipharma, today announce that they have entered into a distribution and license agreement for the exclusive rights to anamorelin in China, Hong Kong and Macao.

26 Mar 2015

Novo Nordisk announces U.S. launch of Novoeight for people living with hemophilia A

Novo Nordisk today announced the company will launch Novoeight (Antihemophilic Factor [Recombinant]) in the United States for people living with hemophilia A.

From Novo Nordisk 26 Mar 2015

Inergetics announces launch of branded CBD-based nutritional supplement

Inergetics,Inc., a world-class developer of NSF Certified nutritional and consumer health products, announced today the launch of Nulief, a branded nutritional supplement offering the holistic benefits associated with Cannabidiol (CBD).

26 Mar 2015

Cellworld 2015 conference to be held in Downtown San Francisco on Sept. 21-22, 2015

Finesse Solutions announced Cellworld 2015, a new event that is specifically designed for innovators, visionaries and senior executives in bio-processing.

26 Mar 2015

Nanolek, Green Cross sign strategic deal to commercialize biologics in the Russian market

Green Cross, a South Korean biopharmaceutical company, and Nanolek, a Russian pharmaceutical company, today announced that they have entered into a strategic partnership agreement for the commercialisation of Green Cross' biologics in the Russian market.

26 Mar 2015

UVA researchers develop compound that could lead to improved leukemia treatments

Researchers at the University of Virginia School of Medicine have developed a compound that delays leukemia in mice and effectively kills leukemia cells in human tissue samples, raising hopes that the drug could lead to improved treatments in people. The researchers call it an exciting "new paradigm" for treating leukemia.

26 Mar 2015

AdverseEvents launches RxCost to determine economic impact of prescribing particular drugs

AdverseEvents Inc., a leading healthcare informatics company, today launched RxCost, the first methodology to identify the total costs of adverse drug reactions (ADRs) associated with FDA-approved drugs.

26 Mar 2015

C3BS plans to open new U.S.-based facility to manufacture C-Cure for use in Phase III trial

Cardio3 BioSciences, a leader in the discovery and development of engineered cell therapies, today confirmed plans to open a new U.S.-based manufacturing facility in Rochester, Minnesota. The facility will support the Company’s current and anticipated manufacturing needs in the United States for both the Phase III clinical trial evaluating lead cardiovascular product candidate C-Cure (CHART-2), and its recently acquired CAR T-cell therapies’ portfolio.

26 Mar 2015

BeyondSpring files two patent applications to expand therapeutic scope of Plinabulin

BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it has filed two new method of treatment patent applications with the United States Patent and Trademark Office to cover methods of treating brain tumors as well as cancers expressing a mutant form of RAS protein through administration of the Company’s lead compound, Plinabulin.

26 Mar 2015

Novasep, Celladon sign agreement to develop and supply MYDICAR drug substance

Novasep, a leading supplier of services and technologies for the life sciences and chemical industries, and Celladon Corporation, a clinical-stage cardiovascular gene therapy company, today announce that they have signed a Development, Manufacturing and Supply Agreement pursuant to which, if supported by upcoming MYDICAR clinical data, Novasep would manufacture MYDICAR drug substance through 2018 with extension options through 2020.

26 Mar 2015

Theravectys gets authorization to produce lentiviral vectors for clinical use and CAR-T cell-based immunotherapy

THERAVECTYS, a clinical development biotechnology company that focuses on the development of therapeutic vaccines and immunotherapies, proudly announces that its manufacturing plant has obtained the status of a pharmaceutical manufacturing establishment, granted by the French National Agency for Medicines and Health Products Safety.

26 Mar 2015

Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the European Commission has granted orphan medicinal product designation for RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21") for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy.

25 Mar 2015

Accelovance named finalist for Best Contract Research Organization at ViE Awards

Accelovance, a therapeutically focused contract research organization (CRO), has been named a finalist for "Best Contract Research Organization" at the upcoming Vaccine Industry Excellence (ViE) Awards hosted by the World Vaccine Congress.

25 Mar 2015

FDA approves Quadracel vaccine to protect young children from life-threatening diseases

Sanofi Pasteur, the vaccines division of Sanofi, announced today that the U.S. Food and Drug Administration has approved use of Quadracel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Absorbed and Inactivated Poliovirus; DTaP-IPV) vaccine for active immunization against diphtheria, tetanus, pertussis and poliomyelitis in children 4 through 6 years of age.

25 Mar 2015

Marken secures Best Life Science Logistics Provider award

Marken announced today that they won the pharmaceutical clinical research industry award of Best Life Science Logistics Provider at the 5th Annual BioPharma Asia Industry Awards. The award was announced at a dinner and ceremony held in conjunction with the BioPharma Asia conference in Singapore, drawing an annual attendance of 1600.

25 Mar 2015

Many teens still ignorant of significant physical danger posed by legal drugs

Legal drugs such as OxyContin now kill more people than heroin and cocaine combined. While awareness of the dangers of illegal drugs has increased, many teens are still ignorant of the significant physical danger posed by legally prescribed drugs, according to a new study in Journal of Public Policy & Marketing.

25 Mar 2015

Only few studies demonstrate the effectiveness of marijuana

While many states have pushed for new laws to legalize the use of marijuana for medical reasons, there are few well-controlled studies that demonstrate its effectiveness.

25 Mar 2015

Oncolytics' REOLYSIN granted EMA Orphan Drug Designation for treatment of gynecological cancers

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the European Medicines Agency has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of ovarian, fallopian tube and primary peritoneal cancers.

25 Mar 2015

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced its plans for the commercialization of SPRIX (ketorolac tromethamine) Nasal Spray and OXAYDO (oxycodone HCI, USP) tablets for oral use only –CII.

25 Mar 2015

Pharmaceutical News

WHO report: Access to new medicines requires transparency, collaboration

Helsinn, Mundipharma sign distribution and license agreement for anamorelin

Novo Nordisk announces U.S. launch of Novoeight for people living with hemophilia A

Inergetics announces launch of branded CBD-based nutritional supplement

Cellworld 2015 conference to be held in Downtown San Francisco on Sept. 21-22, 2015

Nanolek, Green Cross sign strategic deal to commercialize biologics in the Russian market

UVA researchers develop compound that could lead to improved leukemia treatments

AdverseEvents launches RxCost to determine economic impact of prescribing particular drugs

C3BS plans to open new U.S.-based facility to manufacture C-Cure for use in Phase III trial

BeyondSpring files two patent applications to expand therapeutic scope of Plinabulin

Novasep, Celladon sign agreement to develop and supply MYDICAR drug substance

Theravectys gets authorization to produce lentiviral vectors for clinical use and CAR-T cell-based immunotherapy

Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

Accelovance named finalist for Best Contract Research Organization at ViE Awards

FDA approves Quadracel vaccine to protect young children from life-threatening diseases

Marken secures Best Life Science Logistics Provider award

Many teens still ignorant of significant physical danger posed by legal drugs

Only few studies demonstrate the effectiveness of marijuana

Oncolytics' REOLYSIN granted EMA Orphan Drug Designation for treatment of gynecological cancers

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News